AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

Core Insights - AtaiBeckley Inc. is a clinical-stage biotechnology company focused on developing rapid-acting and durable mental health treatments, recently participating in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) [1][6] Group 1: Clinical Data Presentation - Dr. David Feifel presented data from AtaiBeckley's Phase 2b study of BPL-003, showing that a single 8 mg or 12 mg dose resulted in significant, rapid, and sustained antidepressant effects in treatment-resistant depression (TRD) compared to a 0.3 mg control dose, with both active doses well-tolerated [2] - The findings from the Phase 2b study highlight the potential benefits of BPL-003 in treating TRD and indicate the need for further investigation in Phase 3 trials [2] Group 2: Preclinical Research - Dr. Michelle Kokkinou presented a preclinical study on 5-MeO-DMT, indicating its pharmacological and pharmacokinetic profile, which supports its therapeutic use for mood disorders and suggests potential mechanisms related to neuroplasticity [3] Group 3: Company Statements and Future Directions - Dr. Kevin Craig, Chief Medical Officer, expressed satisfaction with the recognition of BPL-003's results as a Hot Topic at ACNP, emphasizing the strength of the clinical findings in TRD and the commitment to breakthroughs in mental health [4] - AtaiBeckley's pipeline includes BPL-003 for TRD, VLS-01 for TRD, and EMP-01 for social anxiety disorder, all in Phase 2 clinical development, along with a drug discovery program for non-hallucinogenic 5-HT2AR agonists [6]